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these2. Although TBM can occur in immunocompetent persons, 
the disease disproportionately affects persons living with HIV 
and children. Malaria also continues to be a global public health 
threat. In 2016, an estimated 216 million cases occurred, 
with 90% of those in Africa3. Due to marked epidemiological 
overlap in the global burden of TB and malaria, co-infection 
does occur. In an Angolan retrospective study of 1,906 
TB inpatients (37% HIV-infected), Plasmodium falciparum 
co-infection occurred in 38% during hospitalization4. 
TBM/malaria co-infection poses a number of management 
challenges. Rifampicin, the cornerstone for drug-sensitive TB 
treatment, is a potent enzyme inducer that increases the expression 
of several hepatic cytochrome P450 (CYP450) enzymes, includ-
ing CYP2A6, CYP2B6, CYP2C, and CYP3A isoenzymes, as 
well as the efflux drug transporter P-glycoprotein5. Peak enzyme 
induction due to rifampicin is mounted ~ 2 weeks post rifampicin 
initiation. This induction alters the pharmacokinetics of drugs 
metabolized by these pathways, reducing plasma concentrations 
of several anti-malarial medications, including artemisinin-based 
drugs, quinine and atovaquone/proguanil. In HIV/TBM/malaria 
co-infection, there are additional interactions between anti- 
retroviral therapy (ART) and anti-malarial medications6.
Here; we present the case of a hospitalized HIV-infected adult 
with HIV/TBM/malaria co-infection, highlighting important 
diagnostic and pharmacokinetic challenges.
Case report
An HIV-infected 32-year-old male presented to Mulago 
National Referral Hospital, Uganda with a 2-week history of 
headache with fevers and a 1-day history of confusion (Figure 1). 
He had been on ART (zidovudine, lamivudine, efavirenz) and 
co-trimoxazole prophylaxis for 5 years. 5 months prior, he 
was diagnosed with pulmonary TB by positive sputum Xpert 
MTB/RIF (Cepheid, Sunnyvale, CA, USA). He had completed 
2 months of induction TB therapy (rifampicin, isoniazid, 
Figure 1. Clinical presentation timeline.
      Amendments from Version 1
It is now explicitly stated that the IV ceftriaxone was discontinued 
when the Xpert result came back at positive.
It is now explicitly stated that there was no evidence of rifampicin 
resistance from the Xpert result.
A sentence has been added noting that is takes approximately  
2 weeks for the full effects of enzyme induction by rifampicin to be 
mounted.
A sentence has been added highlighting the need for a lipid meal 
to be taken prior to lumefantrine to optimise absorption.
The units for CSF opening pressure has been changed from cm 
H20 to cm CSF.
A sentence has been added detailing planned follow up and 
adherence counselling provided.
A paragraph has been added how future research in this 
important area may be conducted.
Re: “Is it common to present with TB meningitis five months into 
therapy where there has been apparent adherence?“
There is no data about the likelihood of TBM after initiation 
treatment for TB-meningitis. On effective quadruple anti-TBs 
with good adherence this is rare. However, this patient may not 
have been on effective quadruple anti-TBs as he reported poor 
adherence to his anti-tuberculous medications. In addition, 
baseline INR-resistance rates are 5-10% in Uganda but not 
routinely tested for; in patients with disseminated TB with 
baseline INH-resistance only PZA is effectively reaching the 
CNS at decent levels (RIF and ETH poor penetration). We also 
know that HIV-status is the strongest predictor of poor outcomes 
in PTB treatment and HIV is likely to negatively impact of PK 
achievements. 
LSHTM-MRC-UVRI Uganda Research Unit, Entebbe, Uganda has 




In 2016, 10.4 million cases of tuberculosis (TB) were reported 
globally1. Tuberculous meningitis (TBM) accounts for 1–5% of 
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ethambutol, pyrazinamide) and was 3 months into continua-
tion phase (rifampicin, isoniazid). He endorsed poor adherence 
to both ART and anti-tuberculous medications.
On examination, the patient was febrile (38.6°C). His blood 
pressure was 112/71 mmHg, pulse 94 beats/minute, respiratory 
rate 48, and oxygen saturation 98%. He was wasted, dehydrated, 
and had overt rigors. His Glasgow Coma Scale was 14/15 with 
nuchal rigidity and positive Kernig’s sign. Cranial nerves were 
intact. He had normal tone and power in all limbs. A clinical 
diagnosis of HIV-associated meningitis was suspected and he 
was recruited into the ‘Improving Diagnostics and Neurocogni-
tive Outcomes in HIV/AIDS-related Meningitis’ study (registra-
tion: ISRCTN42218549). Whilst awaiting further investigations, 
he received empiric therapy of ceftriaxone 2 g twice daily for 
possible bacterial meningitis.
A finger stick cryptococcal antigen lateral flow assay (CrAg 
LFA) (IMMY, Norman, Oklahoma, USA) was negative. Liver 
and renal function tests were normal. Cerebrospinal fluid (CSF) 
opening pressure was elevated to 33 cm CSF (normal <20 cm 
CSF), CSF white cells 590 /µl, protein 419 mg/dl (normal 
range 15–45 mg/dl), CSF lactate 9.5 mmol/L (normal range 
<2.5 mmol/l). CSF glucose was unavailable. Mycobacterium 
tuberculosis in CSF was confirmed on Xpert MTB/RIF Ultra; 
there was no evidence of rifampicin resistance. On day 2, he was 
initiated on dexamethasone at 0.4 mg/kg/day and induction TB-
medications were re-commenced (rifampicin, isoniazid, etham-
butol, pyrazinamide) for TBM. The IV ceftriaxone was stopped, 
his ART was continued. He continued to spike high-grade fevers 
(39.6°C.) with tachycardia (pulse 118 beats/min). A peripheral 
blood smear showed P. falciparum parasites (1+ trophozoites), 
despite a negative malaria histidine rich protein-2 (PfHPR2)- 
based rapid diagnostic test (Malaria Plasmodium falciparum 
Rapid Test Cassette, Vaxpert, Florida, USA). Given his 
ongoing neurological symptoms, which could be compatible with 
cerebral malaria, the decision was made to treat for severe 
malaria. Drug-drug interactions (DDIs) between rifampicin and 
artemisinin compounds, and rifampicin and quinine are recog-
nized (Table 1); a decision was made to treat with IV artesunate 
as the most efficacious anti-malarial for severe malaria6. He 
received three doses of IV artesunate (3 mg/kg), after which a 
repeat peripheral blood smear showed no malaria parasites. He 
then completed 3 days of oral artemether/lumefantrine. His 
fevers subsided on day 6. He was discharged on day 8; medica-
tion adherence counselling was provided for the patient and 
his guardian and outpatient follow-up was arranged for the 
following week.
Discussion
This case demonstrates the diagnostic and treatment challenges 
encountered when managing patients with advanced HIV and 
intercurrent infections. Protracted high-grade fevers are not 
an uncommon feature of TBM, even after appropriate anti- 
tuberculous treatment has been commenced, and it is important 
to remain vigilant for co-infections. Co-infection with HIV- 
TB-malaria is well recognized4; however, to our knowledge this is 
the first published case of HIV-TBM-malaria co-infection.
Due to the potential overlap in symptoms and signs between 
TBM and malaria (fever, confusion, reduced level of con-
sciousness, seizures, sepsis), access to accurate parasitological 
diagnostics is essential. Light microscopy (Giemsa stain) remains 
the gold standard parasitological diagnostic, but the World 
Health Organization (WHO) recommends immunochromato-
graphic rapid diagnostic testing (RDT) in settings with limited 
laboratory facilities6. RDTs—which detect Plasmodium antigens 
such as PfHPR2, Plasmodium lactate dehydrogenase (pLDH) 
or plasmodial aldolase—are the backbone of expanding access 
to malaria diagnostics in resource-limited settings. Since their 
introduction in the late 1990s, the number of RDTs available, 
and the scale of their use, has increased rapidly. A meta-analysis 
of 74 studies assessing accuracy of PfHRP-2 RDTs for diagnosis 
of uncomplicated P. falciparum malaria in endemic settings 
reported average sensitivity and specificity (95% CI) of 
95.0% (93.5-96.2%) and 95.2% (93.4-99.4%), respectively7. 
However RDTs do have several limitations: poor sensitiv-
ity at low parasite densities; susceptibility to the prozone effect 
(PfHRP2-detecting RDTs); false-negative results due to PfHRP2 
gene deletions; false-positive results caused by other infections, 
and susceptibility to heat and humidity8. The largest problem 
historically has been poor manufacturing quality, which the 
World Health Organization (WHO) malaria product testing 
programme has addressed. However, Vaxpert does not partici-
pate in this WHO quality assurance program. As demonstrated 
by this case, false negatives can occur.
The WHO recommends treatment with an artemisinin derivative 
for both uncomplicated (oral artemisinin combination therapy 
(ACT) for 3 days) and complicated falciparum malaria infec-
tions (intravenous or intramuscular artesunate for at least 
24 hours and until the patient can tolerate oral medications, at 
which stage 3 days of ACT should be completed)6. It is recom-
mended that a lipid rich meal is eaten prior to taking lumefan-
trine to optimise absorption. Despite the recognition of potential 
DDIs between first-line anti-malarial drugs and rifampicin, no 
treatment guidelines currently exist for managing patients with 
TB/malaria co-infection. The WHO states that there is currently a 
lack of evidence to recommend dosage modifications but advises 
clinicians of increased risk of recrudescent infections due to 
DDIs in co-infected patients6.
In a DDI study in HIV-infected Ugandans to investigate the 
pharmacokinetics of artemether, dihydroartemisinin (DHA) and 
lumefantrine during rifampicin intake, co-administration with 
rifampicin resulted in a significantly lower exposure (area under 
the curve between 0 and 12 hours post-dosing) to artemether 
(89% lower) and DHA (85% lower)9. Co-administration of 
artemether-lumefantrine and rifampicin should therefore be 
avoided. There are no published studies examining concomitant 
administration of IV artesunate and rifampicin. However, as 
DHA (the active metabolite of artesunate) is metabolized by 
CYP450 enzymes (Table 1), there is a theoretical risk that 
co-administration with rifampicin would result in reduced 
plasma DHA concentrations and a reduction in efficacy5. Oral 
agents may undergo metabolism in the gut and the liver prior 
to reaching the systemic circulation, but intravenous drugs are 
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directly administered to the systemic circulation and so 
reductions in DHA exposure with intravenous artesunate could 
be potentially of lower magnitude than what was seen with oral 
artemether.
Similarly, the bioavailability of quinine—metabolized almost 
exclusively via CYP450 (CYP3A4 and CYP2C19) enzymes—is 
significantly reduced when co-administered with rifampicin 
and has been associated with a clinically significant reduc-
tion in efficacy. Adults treated for uncomplicated falciparum 
malaria were randomized to receive oral quinine either alone or in 
combination with rifampin; recrudescence rates were five times 
higher (15/23; 65%) in the rifampicin arm than those treated 
with quinine alone (3/25; 12%, P<0.001)11. It is recommended 
that for patients already receiving rifampicin, quinine doses 
should be increased. However, to date, no guidance on dose- 
adjustment strategies have been published, and although it is 
advised that therapeutic drug monitoring may be useful, this is 
not feasible in most parts of the world where co-infection 
occurs5.
A range of anti-malarial drugs used in the treatment of 
non-severe malaria and for prophylaxis also have documented 
DDIs with rifampicin including: atovaquone; chloroquine; 
piperaquine; mefloquine and doxycycline (Table 1). As no 
clinical guidelines currently exist regarding dose modification, 
these drugs should be used with caution in patients concurrently 
receiving rifampicin.
Many antiretrovirals also interact with the CYP450 system 
(Table 1). For example, co-administration with efavirenz reduces 
exposure to the active components of artemether and lumefan-
trine 46% and 21%, respectively. However, the net induction 
effects of the use of both rifampicin and efavirenz on 
antimalarial compounds has not been quantified. Similarly, 
protease inhibitors are potent CYP450 inhibitors and their 
combined effect with rifampicin induction is unknown.
This case highlighted the difficulty in managing co-infected 
patients and the lack of informed treatment options. New anti-
malarial medication development have the potential to offer 
improved potency, tolerability, and shorter treatment duration 
but drug- drug interactions are likely to persist. In cases of sus-
pected significant interactions, healthy volunteer studies may play 
a role in informing management as efficient study designs allow 
for small sample sizes. Our group has also employed build-
ing in pharmacokinetic sampling and analysis into existing 
clinical trials. Coupling sparse or opportunistic sampling with 
pharmacokinetic modeling and simulation can allow for increased 
precision in dose selection.
Conclusions
In conclusion, patients with HIV-TBM-malaria co-infection 
present a number of management challenges. The potential 
symptom overlap in clinical presentation means that clinicians 
must remain vigilant for co-infection and access to reliable 
parasitological diagnostics is imperative. As malaria RDT use 
continues to expand, it is essential that clinicians are aware of 
the potential for false negative results. Therapeutic options for 
TB-malaria co-infection are limited due to DDIs. There is both 
an urgent need for the development of new anti-malarial drugs 
which do not interact with rifampicin and for pharmacoki-
netic studies to guide dose modification of existing anti-malarial 
drugs to inform clinical practice guidelines.
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